Leidos Downgraded on Health Care Pressure; Defense Strength Not Enough

What happened

BofA Securities downgraded Leidos Holdings, citing intensifying pressure across its health care portfolio, which offsets the company's well-aligned defense business with the U.S. Department of Defense. This aligns with the DeepValue master report's HOLD stance, which flagged the health care portfolio as a vulnerability despite strong visibility from a $46.2B backlog and robust cash flows. The report noted that Leidos shares trade at ~17x P/E near peers, limiting upside, and highlighted recent headwinds like a DHS contract termination. The downgrade underscores that the health care weakness is more pronounced than earlier assumed, adding to the balanced risk/reward profile. While Leidos' defense and federal IT segments provide a buffer, the health care pressure could weigh on near-term sentiment and margins.

Implication

Over the long term, the thesis remains balanced: Leidos' defense and civil IT contracts provide a solid foundation, but the health care woes could persist, delaying any re-rating. Investors should monitor health care segment margins and bookings for signs of recovery before turning constructive. The downgrade adds a negative catalyst that may keep the stock range-bound near peer valuations.

Thesis delta

The thesis shifts from a balanced HOLD to a more cautious leaning, as the analyst downgrade confirms that health care headwinds are a material drag rather than a transitory issue. While the defense portfolio remains strong, the health care pressure reduces the likelihood of near-term multiple expansion or an upgrade catalyst. The watch items now emphasize health care recovery as a prerequisite for a more bullish stance.